1. Immunology/Inflammation
  2. Interleukin Related
  3. Tocilizumab

Tocilizumab (Synonyms: Anti-Human IL6R, Humanized Antibody)

Cat. No.: HY-P9917 Purity: 99.67%

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).

For research use only. We do not sell to patients.

Tocilizumab Chemical Structure

Tocilizumab Chemical Structure

CAS No. : 375823-41-9

Size Price Stock Quantity
1 mg USD 280 In-stock
Estimated Time of Arrival: December 31
5 mg USD 670 In-stock
Estimated Time of Arrival: December 31
25 mg USD 2500 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4].

IC50 & Target[1][2]

IL-6

 

In Vitro

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml[1].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells[3].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[2]

Cell Line: Human-derived HARA-B cells
Concentration: 1 ng/mL, 10 ng/mL, and 100 ng/mL
Incubation Time: 24 hours, 48 hours
Result: Inhibited the IL-6R expressed on human-derived HARA-B cells.

Cell Cytotoxicity Assay[1]

Cell Line: Ba/F3-gp130-IL-6R cells
Concentration: 0.001–10000 μg/ml
Incubation Time: 2 days
Result: Inhibited Ba/F3-gp130-IL-6R cell proliferation.

Western Blot Analysis[3]

Cell Line: SAS cells
Concentration: 1 μM
Incubation Time: 6 hours
Result: Reduced the phosphorylation of STAT3.

RT-PCR[3]

Cell Line: SAS cells
Concentration: 1-5 μM
Incubation Time: 24 hours
Result: Reduced VEGF mRNA expression.
In Vivo

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2]
Dosage: 1.0 mg/100 μL
Administration: Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks
Result: Led the volume of each metastatic focus significantly smaller.
Animal Model: SCID mice with SAS cells[3]
Dosage: 100 μg/mL
Administration: Intraperitoneal injection;100 μg/mL; every 48 hours; 20days
Result: Suppressed the growth of advanced tumors.
Clinical Trial
CAS No.
Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

Purity: 99.67%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tocilizumab
Cat. No.:
HY-P9917
Quantity:
MCE Japan Authorized Agent: